Dose Optimization Using Population PK for an Orphan Drug
RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…
Certara2021年11月17日
Defining path-to-market strategy through a data-driven and scientific approach
How Certara supported a gene therapy manufacturer by using a selection of gateway and value…
Certara2021年10月28日
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
Certara2021年9月23日
Succeeding in Value Communication: Introduction
Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…
Certara2021年8月5日
What is BaseCase?
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…
Certara2021年7月20日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…
Certara2021年6月18日
Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
Certara2021年6月11日
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
Certara2021年6月11日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021年5月26日
